

# Pieter van Baal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2352905/publications.pdf>

Version: 2024-02-01

31  
papers

531  
citations

687363

13  
h-index

677142

22  
g-index

32  
all docs

32  
docs citations

32  
times ranked

707  
citing authors

#	ARTICLE	IF	CITATIONS
1	When is it too expensive? Cost-effectiveness thresholds and health care decision-making. <i>European Journal of Health Economics</i> , 2019, 20, 175-180.	2.8	73
2	DYNAMO-HIA – A Dynamic Modeling Tool for Generic Health Impact Assessments. <i>PLoS ONE</i> , 2012, 7, e33317.	2.5	51
3	Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 237-248.	1.7	41
4	Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets. <i>Population Health Metrics</i> , 2011, 9, 17.	2.7	39
5	A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. <i>Health Economics (United Kingdom)</i> , 2019, 28, 87-100.	1.7	39
6	The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. <i>Preventive Medicine</i> , 2008, 46, 127-132.	3.4	28
7	Health care input constraints and cost effectiveness analysis decision rules. <i>Social Science and Medicine</i> , 2018, 200, 59-64.	3.8	26
8	Future unrelated medical costs need to be considered in cost effectiveness analysis. <i>European Journal of Health Economics</i> , 2019, 20, 1-5.	2.8	25
9	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. <i>Health Economics (United Kingdom)</i> , 2016, 25, 933-938.	1.7	23
10	Forecasting differences in life expectancy by education. <i>Population Studies</i> , 2016, 70, 201-216.	2.1	20
11	Economics and public health: engaged to be happily married!. <i>European Journal of Public Health</i> , 2007, 17, 122-123.	0.3	15
12	Does living longer in good health facilitate longer working lives? The relationship between disability and working lives. <i>European Journal of Public Health</i> , 2015, 25, 791-795.	0.3	14
13	Should cost effectiveness analyses for NICE always consider future unrelated medical costs?. <i>BMJ: British Medical Journal</i> , 2017, 359, j5096.	2.3	14
14	Realistic Spatial Backcloth is not that Important in Agent Based Simulation Research. , 2008, , 19-34.		13
15	Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.. <i>Pharmacoeconomics</i> , 2013, 31, 369-373.	3.3	12
16	The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1005-1019.	1.7	12
17	Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands. <i>Value in Health</i> , 2022, 25, 731-735.	0.3	12
18	Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0. <i>Value in Health</i> , 2020, 23, 1453-1461.	0.3	11

#	ARTICLE	IF	CITATIONS
19	Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. Cost Effectiveness and Resource Allocation, 2020, 18, 13.	1.5	11
20	The economics of improving global infectious disease surveillance. BMJ Global Health, 2021, 6, e006597.	4.7	11
21	Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. Value in Health, 2020, 23, 1027-1033.	0.3	10
22	Prospective impact of tobacco eradication and overweight and obesity eradication on future morbidity and health-adjusted life expectancy: simulation study. Journal of Epidemiology and Community Health, 2020, 74, 354-361.	3.7	7
23	Trends in Dutch hospital spending by age and disease 1994-2010. Health Policy, 2015, 119, 316-323.	3.0	6
24	The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. Pharmacoeconomics, 2022, 40, 233-239.	3.3	4
25	Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature. European Journal of Health Economics, 2020, 21, 1329-1350.	2.8	3
26	Distributional consequences of including survivor costs in economic evaluations. Health Economics (United Kingdom), 2021, 30, 2606-2613.	1.7	3
27	Estimating the costs of non-medical consumption in life-years gained for economic evaluations. Social Science and Medicine, 2021, 289, 114414.	3.8	3
28	Improving maternal and child health in Pakistan: a programme evaluation using a difference in difference analysis. BMJ Global Health, 2021, 6, e006453.	4.7	3
29	LONG-TERM EFFECTS OF ALCOHOL POLICIES: AN ECONOMIC PERSPECTIVE. Addiction, 2010, 105, 395-397.	3.3	1
30	PAID 1.0 in Practice. Pharmacoeconomics, 2011, 29, 545-547.	3.3	1
31	Important cost categories not included: transcatheter aortic valve implantation probably less cost-effective. Heart, 2012, 98, 1182.1-1182.	2.9	0